Öz
Giriş: Şiddetli akut solunum yolu sendromu-Koronavirüs-2 (SARS-CoV-2) antikorları, virüsle enfekte olmuş veya aşısını olmuş kişilerde oluşur. Bu antikorların dinamikleri, nötralizasyon kapasiteleri gibi birçok özelliği hala netliğe kavuşmamıştır. Konağın immün yanıtının anlaşılması; uygun tedavi yöntemlerinin, aşıların ve epidemiyolojik kontrol stratejilerinin geliştirilmesi için oldukça önemlidir. Bu çalışma, SARS-CoV-2 enfeksiyonu teşhisi konan bireylerde antikor düzeylerinin zaman içindeki değişimini izlemeyi ve nötralizasyon kapasitelerini belirlemeyi amaçlamaktadır. Gereç ve
Yöntem: SARS-CoV-2 enfeksiyonlu hastalardan aylık olarak alınan serum örneklerinde farklı kitler kullanılarak anti-nükleokapsid ve antispike antikor titreleri ölçüldü. Nötralize edici antikorlar, mikronötralizasyon yöntemi ile belirlendi.
Bulgular: Hafif-orta dereceli hastalık seyri olan 43 hastadan alınan toplam 134 serum örneği analiz edildi. Anti-spike antikor pozitifliği, pozitif polimeraz zincir reaksiyonu testinin ardından en erken yedinci günde, en geç 334. günde tespit edildi. Ortalama antikor düzeylerinin üçüncü aydan sonra kademeli olarak yükseldiği ve altıncı aydan sonra azalmaya başladığı gözlendi. Anti-nükleokapsid IgM ve IgG antikorları tek başına veya kombinasyon halinde tespit edildi. En yüksek nötralize edici antikor titresi ilk ayda 1/80 iken, dört ay sonra 1/10’un altına düştüğü belirlendi.
Sonuç: Farklı antijenlere karşı antikorların saptanması veya total antikorların test edilmesi için kitlerin birlikte kullanılması, yedinci günde ortaya çıkmaya başlayan ve SARS-CoV’dan altı ay sonra azalan antikorların daha doğru ve daha erken saptanmasını sağlayacaktır. Ayrıca nötralizan antikor titrelerinin dört ay sonra dramatik olarak azalması, erken reenfeksiyonların nedenlerinden biri olabilir.
Anahtar Kelimeler: Koronavirüs hastalığı-2019, anti-SARS-CoV-2 antikoru, nötralizan antikor
Kaynakça
Lei Q, Li Y, Hou HY, Wang F, Ouyang ZQ, Zhang Y, Lai DY, Banga Ndzouboukou JL, Xu ZW, Zhang B, Chen H, Xue JB, Lin XS, Zheng YX, Yao ZJ, Wang XN, Yu CZ, Jiang HW, Zhang HN, Qi H, Guo SJ, Huang SH, Sun ZY, Tao SC, Fan XL. Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections. Allergy. 2021;76:551-61.
Ejazi SA, Ghosh S, Ali N. Antibody detection assays for COVID-19 diagnosis: an early overview. Immunol Cell Biol. 2021;99:21-33.
Özçürümez MK, Ambrosch A, Frey O, Haselmann V, Holdenrieder S, Kiehntopf M, Neumaier M, Walter M, Wenzel F, Wölfel R, Renz H; COVID-19 Task Force of the German Society for Clinical Chemistry and Laboratory Medicine (DGKL). SARS-CoV-2 antibody testing-questions to be asked. J Allergy Clin Immunol. 2020;146:35-43.
Durmaz B. Microbiological Diagnosis in COVID-19 Infection. Journal of Health Science Yuksek Ihtisas University. 2020;1:12-7.
Ali MG, Zhang Z, Gao Q, Pan M, Rowan EG, Zhang J. Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview. Immunol Res. 2020;68:325-39.
Zhao J, Zhao S, Ou J, Zhang J, Lan W, Guan W, Wu X, Yan Y, Zhao W, Wu J, Chodosh J, Zhang Q. COVID-19: Coronavirus Vaccine Development Updates. Front Immunol. 2020;11:602256.
Liu A, Li Y, Peng J, Huang Y, Xu D. Antibody responses against SARS-CoV-2 in COVID-19 patients. J Med Virol. 2021;93:144-8.
Amanat F, White KM, Miorin L, Strohmeier S, McMahon M, Meade P, Liu WC, Albrecht RA, Simon V, Martinez-Sobrido L, Moran T, García-Sastre A, Krammer F. An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening. Curr Protoc Microbiol. 2020;58:e108.
Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, Gao H, Ge X, Kan B, Hu Y, Liu J, Cai F, Jiang D, Yin Y, Qin C, Li J, Gong X, Lou X, Shi W, Wu D, Zhang H, Zhu L, Deng W, Li Y, Lu J, Li C, Wang X, Yin W, Zhang Y, Qin C. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369:77-81.
Wang B, Wang L, Kong X, Geng J, Xiao D, Ma C, Jiang XM, Wang PH. Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients. J Med Virol. 2020;92:1684-9.
Liu A, Li Y, Peng J, Huang Y, Xu D. Antibody responses against SARS-CoV-2 in COVID-19 patients. J Med Virol. 2021;93:144-8.
Younes N, Al-Sadeq DW, Al-Jighefee H, Younes S, Al-Jamal O, Daas HI, Yassine HM, Nasrallah GK. Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2. Viruses. 2020;12:582.
Jääskeläinen AJ, Kuivanen S, Kekäläinen E, Ahava MJ, Loginov R, Kallio-Kokko H, Vapalahti O, Jarva H, Kurkela S, Lappalainen M. Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation. J Clin Virol. 2020;129:104512.
Gao YD, Ding M, Dong X, Zhang JJ, Kursat Azkur A, Azkur D, Gan H, Sun YL, Fu W, Li W, Liang HL, Cao YY, Yan Q, Cao C, Gao HY, Brüggen MC, van de Veen W, Sokolowska M, Akdis M, Akdis CA. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76:428-55.
Lee YL, Liao CH, Liu PY, Cheng CY, Chung MY, Liu CE, Chang SY, Hsueh PR. Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients. J Infect. 2020;81:e55-8.
Wang B, Wang L, Kong X, Geng J, Xiao D, Ma C, Jiang XM, Wang PH. Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients. J Med Virol. 2020;92:1684-9.
Laing ED, Epsi NJ, Richard SA, Samuels EC, Wang W, Vassell R, Ewing DF, Herrup R, Sterling SL, Lindholm DA, Millar EV, Maves RC, Larson DT, Colombo RE, Chi S, Madar C, Lalani T, Ganesan A, Fries A, Colombo CJ, Mende K, Simons MP, Schully KL, Weiss CD, Burgess TH, for the EPICC Study team. SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody 2 magnitude is associated with age and COVID-19 severity. medRxiv. doı:10.1101/2021.04.27.21256207.
Crawford KHD, Dingens AS, Eguia R, Wolf CR, Wilcox N, Logue JK, Shuey K, Casto AM, Fiala B, Wrenn S, Pettie D, King NP, Greninger AL, Chu HY, Bloom JD. Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Infect Dis. 2021;3;223:197-205.
Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect. 1990;105:435-46.
Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol. 2020;101:791-7.
Ong DSY, Fragkou PC, Schweitzer VA, Chemaly RF, Moschopoulos CD, Skevaki C; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV). How to interpret and use COVID-19 serology and immunology tests. Clin Microbiol Infect. Clin Microbiol Infect. 2021;27:981-6.
Føns S, Krogfelt KA. How can we interpret SARS-CoV-2 antibody test results? Pathog Dis. 2021;79:ftaa069.
Van Elslande J, Decru B, Jonckheere S, Van Wijngaerden E, Houben E, Vandecandelaere P, Indevuyst C, Depypere M, Desmet S, André E, Van Ranst M, Lagrou K, Vermeersch P. Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs. Clin Microbiol Infect. 2020;26:1557.e1-7.
To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, Yip CC, Cai JP, Chan JM, Chik TS, Lau DP, Choi CY, Chen LL, Chan WM, Chan KH, Ip JD, Ng AC, Poon RW, Luo CT, Cheng VC, Chan JF, Hung IF, Chen Z, Chen H, Yuen KY. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20:565-74.
Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ, Su K, Zhang F, Gong J, Wu B, Liu XM, Li JJ, Qiu JF, Chen J, Huang AL. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26:1200-4.
Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier A, Nakao C, Rayaprolu V, Rawlings SA, Peters B, Krammer F, Simon V, Saphire EO, Smith DM, Weiskopf D, Sette A, Crotty S. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371:eabf4063.
Grzelak L, Temmam S, Planchais C, Demeret C, Tondeur L, Huon C, Guivel-Benhassine F, Staropoli I, Chazal M, Dufloo J, Planas D, Buchrieser J, Rajah MM, Robinot R, Porrot F, Albert M, Chen KY, Crescenzo-Chaigne B, Donati F, Anna F, Souque P, Gransagne M, Bellalou J, Nowakowski M, Backovic M, Bouadma L, Le Fevre L, Le Hingrat Q, Descamps D, Pourbaix A, Laouénan C, Ghosn J, Yazdanpanah Y, Besombes C, Jolly N, Pellerin-Fernandes S, Cheny O, Ungeheuer MN, Mellon G, Morel P, Rolland S, Rey FA, Behillil S, Enouf V, Lemaitre A, Créach MA, Petres S, Escriou N, Charneau P, Fontanet A, Hoen B, Bruel T, Eloit M, Mouquet H, Schwartz O, van der Werf S. A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. Sci Transl Med. 2020;12:eabc3103.
Brochot E, Demey B, Touzé A, Belouzard S, Dubuisson J, Schmit JL, Duverlie G, Francois C, Castelain S, Helle F. Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals. Front Microbiol. 2020;11:584251.
Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, Ling Y, Zhang Y, Xun J, Lu L, Jiang S, Lu H, Wen Y, Huang J. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv. https://www.medrxiv.org/content/10.1101/2020.03.30.20047365v2.
Batra M, Tian R, Zhang C, Clarence E, Sacher CS, Miranda JN, De La Fuente JRO, Mathew M, Green D, Patel S, Bastidas MVP, Haddadi S, Murthi M, Gonzalez MS, Kambali S, Santos KHM, Asif H, Modarresi F, Faghihi M, Mirsaeidi M. Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes. Sci Rep. 2021;11:3455.
Van Elslande J, Vermeersch P, Vandervoort K, Wawina-Bokalanga T, Vanmechelen B, Wollants E, Laenen L, André E, Van Ranst M, Lagrou K, Maes P. Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection by a Phylogenetically Distinct Strain. Clin Infect Dis. 2021;73:354-6.
